BrainSee
Overview
Darmiyan is a pioneering brain health technology company focused on developing innovative and rapidly scalable products for brain health screening and monitoring. Its flagship product, BrainSee, is an AI-powered virtual microscope of the human brain designed for the early detection, visualization, and quantification of neurodegenerative disorders, specifically Alzheimer’s disease. BrainSee leverages cutting-edge image processing and medical Artificial Intelligence to predict the likelihood of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer’s dementia within a five-year timeframe. It seamlessly integrates standard clinical brain MRI and cognitive assessments to generate an objective risk score, aiming to redefine brain health screening and monitoring standards.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered whole-brain image analysis
- Predicts progression from aMCI to Alzheimer's dementia within 5 years
- Utilizes standard clinical brain MRI and cognitive assessments (MMSE, CDR-SB)
- Generates an objective risk score (0-100)
- Non-invasive
- High prognostic accuracy (91% in studies)
- Same-day test results
- Secure, HIPAA-compliant web portal
- Integrates effortlessly into existing clinical workflows
- Virtual Microscope technology (DarmiScope)
Use Cases
- Early detection and prognosis of Alzheimer's disease
- Risk stratification for patients with amnestic mild cognitive impairment (aMCI)
- Guiding early intervention and personalized treatment strategies
- Reducing the need for costly and invasive tests
- Identifying optimal candidates for Alzheimer's clinical trials
- Monitoring risk and treatment efficacy over time
What Physicians Need to Know
BrainSee provides an objective, non-invasive prognostic tool for patients with amnestic MCI, helping to guide early intervention strategies and manage patient expectations. It can be used to identify suitable candidates for clinical trials and monitor patient response to interventions. The platform is accessible to any licensed physician, including general practitioners, geriatricians, psychiatrists, and preventive medicine specialists. The test can be repeated annually or more frequently to monitor risk changes based on treatments and lifestyle modifications.
BrainSee is accessible to physicians through a secure, HIPAA-compliant web portal. The platform supports remote doctor visits, comprehensive cognitive assessments, MRI prescriptions, and follow-ups. Darmiyan is also exploring collaborations to integrate BrainSee's AI platform into early Alzheimer's disease trial design for pharmaceutical companies.
Details
| Category | Neurology AI, Radiology & Imaging AI |
| Pricing | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Geriatrics, Neurology, Radiology |
What the Web Says
BrainSee, developed by Darmiyan, is an AI-powered clinical tool that analyzes standard brain MRI and cognitive assessments to predict the likelihood of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer's dementia within five years. It received FDA De Novo approval in January 2024, marking it as a first-of-its-kind non-invasive prognostic tool for Alzheimer's. Physicians and experts have expressed optimism about its potential to redefine brain health screening and enable earlier, more personalized interventions.
Overall: PositiveStrengths
- Predicts progression from aMCI to Alzheimer's dementia within 5 years with reported 91% accuracy.
- Non-invasive, utilizing standard clinical brain MRI and cognitive assessments.
- Provides objective scores to help physicians determine patient prognosis.
- Aids in early screening and risk stratification, potentially delaying dementia onset through timely treatments.
- Reduces the need for costly and invasive tests for low-risk patients.
- Seamless integration into clinical workflow with same-day test results.
Limitations
- The FDA approval is for adjunctive use, meaning it's not a stand-alone diagnostic or prognostic tool and should not be used to diagnose aMCI.
- Some experts suggest that peer-reviewed studies are needed to fully understand the sensitivity and specificity of the approach.
- The sensitivity in one pivotal study fell below the pre-specified goal.
- The algorithm's reliance on hippocampal atrophy as a key predictive feature has been noted, and its contribution within the 'black box' of the AI needs further understanding.
- While BrainSee is available to physicians, there is no information about direct patient access or cost.
- No reviews from Reddit, G2, or Capterra specifically for Darmiyan's BrainSee were found.
Based on reviews from: Darmiyan, PR Newswire, MCRA, med-tech.world, Engadget, Practical Neurology, MedTech Innovator, Alzheimer's News Today, Medical Device Network, Healthcare Discovery AI, Reportable News, AuntMinnie.com, Alzforum, BrainSee.ai, notebookcheck.net, notebookcheck.nl, Capterra
Last updated: 2026-10-29
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate BrainSee
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for BrainSee.
No videos found. Search YouTube directly
